ArticleFrontiers in cell and developmental biology2025
The role of IGF-2 and its variants in enhancing endothelial migration and angiogenesis.
Article in Frontiers in cell and developmental biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Epitranscriptomic regulation of diabetic EndMT in HAECs: METTL3-dependent mFunctional & integrative genomics · 2026Article
- CPNE7-derived peptides CDP4 and UG28 as pro-angiogenic factors for endothelial regeneration.Frontiers in pharmacology · 2026Article
- From renal development to pathology: An analysis of the multilevel role of insulin‑like growth factor 2 (Review).Molecular medicine reports · 2026Review
- Cardiovascular Dysfunction in Type 2 Diabetes: The Role of MicroRNAs.Handbook of experimental pharmacology · 2026Review
- Vitamin D deficiency in mice modulates oral microbiome stability over time and leads to changes in host inflammatory gene expression pathways.Frontiers in cellular and infection microbiology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Angiogenesis, the formation of new blood vessels, is essential for physiological processes such as tissue repair as well as pathological conditions including cancer. While insulin-like growth factor 2 (IGF-2) is identified as a key regulator of angiogenesis, the contributions of its variants remain less explored. Methods: We compared the effects of wildtype IGF-2 with that of Des(1-6)IGF-2, which has lower affinity to IGF-binding proteins (IGFBPs), and Leu27IGF2, which interacts selectively with the IGF-Receptor 2. We analyzed their effect on endothelial cell migration and tube formation as well as on the secretome of endothelial cells using an antibody array. In addition, the regulatory influence of IGF-binding protein 6 (IGFBP-6) in modulating these effects was investigated. Finally, the ability of the three different variants of IGF-2 to induce blood vessel formation was studied using the chicken 'chorioallantoic membrane' (CAM) assay. Results: IGF-2 and Des(1-6)IGF-2 significantly promoted endothelial cell migration and tube formation Conclusion: These results suggest that Des(1-6)IGF-2 may serve as a potent pro-angiogenic agent with therapeutic potential, while IGFBP-6 could offer a strategy for suppressing pathological angiogenesis.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.